Clinical Guides
Prostate Cancer
A clinically focused, India-adapted guide to risk-aware prostate cancer assessment, MRI-informed biopsy, staging and shared multidisciplinary treatment, with explicit limits on PSA, foreign guidance and resource-dependent pathways.
MedNext Academy | 13 min read
Prostate Cancer
A clinically focused, India-adapted guide to risk-aware prostate cancer assessment, MRI-informed biopsy, staging and shared multidisciplinary treatment, with explicit limits on PSA, foreign guidance and resource-dependent pathways.
Summary
Prostate cancer is usually an acinar adenocarcinoma whose behaviour ranges from indolent, organ-confined disease to rapidly progressive metastatic cancer. Finding cancer is not the same as proving that immediate treatment will improve a person’s life. The core clinical task is to separate benign causes of urinary symptoms and PSA elevation from clinically significant cancer, confirm histology when appropriate, assign Grade Group and TNM stage, and integrate cancer risk with life expectancy, frailty, comorbidity and patient preference. PSA is organ-specific rather than cancer-specific: benign enlargement, inflammation, retention and recent manipulation can raise it, while some important cancers occur without a dramatic elevation. A suspicious digital rectal examination warrants evaluation regardless of one PSA value. Contemporary diagnostic pathways use good-quality multiparametric MRI before biopsy where available, followed by targeted and systematic sampling when indicated; the ICMR 2023 consensus favours transperineal systematic biopsy because of lower infection risk. Localised low-risk disease may be managed safely with structured active surveillance, whereas suitable higher-risk disease requires radical prostatectomy or radiotherapy, sometimes combined with androgen deprivation. Metastatic treatment usually begins with androgen deprivation plus evidence-based intensification selected by fitness, disease volume, access and contraindications. Management must preserve function as well as survival by addressing urinary control, sexual health, bone health, metabolic and cardiovascular risk, pain and psychological burden. All definitive decisions belong in a urological cancer multidisciplinary team, not in a PSA-only algorithm.
How Common Is It?
The recorded burden of prostate cancer in India is heterogeneous. The ICMR 2023 consensus states that prostate cancer features among the ten leading male cancers in several urban registries, including Bengaluru, Delhi, Bhopal and Mumbai, while recorded rural burden is lower. It also describes increasing incidence in parts of India and identifies longer life expectancy, detection, awareness and lifestyle change as possible contributors. These observations do not establish one national incidence rate. The ICMR-NCDIR National Cancer Registry Programme compiles data from defined population- and hospital-based registries; differences in age structure, case ascertainment, PSA testing, pathology access and registry coverage influence comparisons. Tertiary urology and oncology centres also see a selected population and cannot represent community prevalence. International statements that prostate cancer is among the most common male cancers are useful for global context but cannot be transplanted into an Indian screening estimate. Clinically, recorded incidence will rise when previously undiagnosed disease is detected, yet more testing also finds indolent tumours that may never have caused harm. Burden should therefore be discussed alongside stage at presentation, mortality, treatment access and overdiagnosis. A clinician should not reassure a symptomatic or high-risk individual merely because local population rates are lower than in Western countries, nor imply that every asymptomatic man benefits from PSA testing. Use dated registry evidence for population claims and individualised shared decision-making for testing.
Risk Factors
Advancing age is the dominant risk factor. A first-degree relative with prostate cancer, especially early-onset or multiple affected relatives, increases risk; germline variants including BRCA2 and other DNA-repair genes can identify families with more aggressive disease and implications beyond one patient. Ask about prostate, breast, ovarian and pancreatic cancers across the pedigree rather than recording only a vague positive family history. Ancestry modifies risk in international datasets, but population estimates from Black African-Caribbean cohorts should not be assumed to quantify risk for every Indian ethnic group. Obesity, metabolic health, diet, tobacco and occupational exposures have been studied, yet they do not offer a sufficiently specific causal profile to diagnose or exclude prostate cancer. Lower urinary tract symptoms are common with benign prostatic enlargement and are not themselves a reliable cancer-risk score. Previous PSA results, prostate volume, digital rectal examination, MRI, prior biopsy and 5-alpha-reductase inhibitor use all change interpretation. Finasteride or dutasteride can lower PSA, so the medication and duration must be disclosed rather than applying an unrecorded correction mechanically. Prostatitis, urinary retention, ejaculation, catheterisation and recent instrumentation may transiently influence PSA. Risk assessment should support an informed decision about testing or genetic referral, not create false certainty. Explain that screening can detect potentially lethal disease earlier but can also lead to false positives, biopsy harms, overdiagnosis and treatment of cancers unlikely to shorten life. Local policy, age, health status and preference matter.
Diagnosis
History
Ask why PSA was measured and retrieve previous values, assay dates and transient influences. Clarify urinary storage and voiding symptoms, visible haematuria, haematospermia, pelvic or bone pain, weight loss, weakness and neurological symptoms. Record urinary infection, retention, catheterisation, biopsy, surgery, 5-alpha-reductase inhibitor use, anticoagulation, family cancer history, performance status, life expectancy, continence, sexual function and treatment priorities. Symptoms may be absent in localised disease.
Examination
Assess general condition, frailty and signs of anaemia or advanced disease. Examine abdomen for bladder distension and masses. With consent and a chaperone according to local policy, perform digital rectal examination for asymmetry, induration, nodularity, loss of the median sulcus or fixation; estimate size and document findings. Examine lymph nodes, spine and neurology when metastatic disease is suspected. A normal examination does not exclude cancer, and a suspicious examination should not be dismissed because PSA is modest.
Investigations
Repeat an unexpectedly raised PSA under standardised conditions when clinically safe, check urinalysis or culture if infection is suspected, and assess renal function when obstruction is possible. Do not prescribe antibiotics solely to make an asymptomatic PSA fall. Use PSA, prostate volume or density, trajectory, examination, age, comorbidity and family risk together. Where available, obtain multiparametric MRI before first biopsy and report with a validated score. Biopsy decisions require shared discussion of false negatives, infection, bleeding and overdiagnosis; combine targeted and systematic cores when indicated, preferably through a transperineal pathway with local antimicrobial governance. Histology reports Gleason pattern and ISUP Grade Group. Stage according to risk using appropriate pelvic imaging and metastatic assessment; PSMA PET/CT can improve staging in selected settings but availability and indication must be specialist-defined.
Differential Diagnosis
Benign prostatic hyperplasia commonly causes frequency, urgency, nocturia, weak stream and incomplete emptying, often with a smooth enlarged gland. Symptoms and gland size do not reliably separate it from cancer, and both conditions can coexist. Acute bacterial prostatitis typically produces systemic illness, pelvic pain and urinary symptoms; avoid vigorous prostatic massage and treat sepsis promptly. Chronic prostatitis or chronic pelvic pain syndrome may cause fluctuating discomfort without the cancer pattern. Urinary infection, retention, recent catheterisation, cystoscopy, biopsy and ejaculation can alter PSA transiently. Prostatic infarction and trauma are less common causes. A hard or irregular gland may reflect cancer but calcification, previous inflammation or treatment can complicate examination. Urothelial carcinoma, bladder stone, urethral stricture and neurogenic bladder may present with lower urinary tract symptoms or haematuria. Bone pain in an older man has many causes, including degenerative disease, myeloma and other malignancies; metastatic prostate cancer becomes more likely when pain, PSA, alkaline phosphatase and imaging align, but no single feature is definitive. After treatment, a rising PSA can represent biochemical recurrence, residual benign tissue in some contexts or assay variation, and should be interpreted using the treatment-specific definition and trend. The key error is anchoring: urinary symptoms are not automatically benign, while an elevated PSA is not automatically cancer. Resolve the differential with repeat assessment, MRI, histopathology and risk-appropriate staging rather than an empirical drug trial that delays diagnosis.
Management
Begin with multidisciplinary classification: clinical stage, Grade Group, PSA, imaging, genomic or germline information when indicated, symptoms, fitness and estimated life expectancy. Distinguish active surveillance from watchful waiting. Active surveillance is a curative-intent monitoring strategy for appropriately selected localised disease, using a defined schedule and triggers for reassessment; watchful waiting is symptom-led conservative care when competing mortality or preference makes curative treatment inappropriate. Suitable localised disease may be treated with radical prostatectomy or radical radiotherapy, with candid counselling on oncological control, urinary incontinence, erectile dysfunction, bowel effects and salvage options. Higher-risk localised or locally advanced disease often needs radiotherapy with androgen deprivation, or surgery within a plan that anticipates additional therapy. Do not offer focal therapy as routine care outside evidence-based specialist governance. In metastatic castration-sensitive disease, androgen deprivation alone is usually insufficient for a fit patient; combine it with an androgen-receptor pathway agent and/or docetaxel in an evidence-based, individualised strategy. Maintain castrate testosterone in castration-resistant disease while selecting subsequent systemic, radiopharmaceutical, targeted or chemotherapy options by prior exposure, symptoms, molecular findings and access. Urgent complications, including spinal cord compression and obstructive renal failure, take priority. Throughout care, monitor PSA and clinical status using treatment-specific schedules, manage cardiovascular and metabolic risk, protect bone, treat pain, and integrate rehabilitation, sexual-health, continence and palliative services. The 2023 ICMR consensus is the principal Indian framework, but current approvals and institutional protocols still govern treatment.
Prescribing Information
Androgen deprivation can be achieved surgically or medically and requires informed discussion, not a reflex prescription. Gonadotropin-releasing hormone agonists can produce an initial testosterone flare; tumour-flare protection and timing matter in a patient at risk of obstruction, severe bone pain or neurological compromise. Antagonists avoid flare but have distinct administration and access considerations. Bilateral orchidectomy remains an effective, low-maintenance option for some metastatic patients and should be discussed without stigma when clinically suitable. Androgen-receptor pathway inhibitors differ in corticosteroid requirements, hepatic effects, hypertension, fluid retention, falls, fatigue, seizure risk, interactions and financial burden. Docetaxel requires fitness assessment, blood-count and organ-function monitoring, infection precautions and protocolled supportive care. Bone-protective medicines are not interchangeable with simple calcium advice: establish indication, renal function, calcium and vitamin D status, dental risk and the difference between osteoporosis prevention and skeletal-event prevention in metastatic disease. Long-term androgen deprivation can worsen hot flushes, sexual function, muscle mass, bone density, glucose, lipids and cardiovascular risk, so measure and manage these domains proactively. Avoid routine antibiotics for an isolated PSA rise; when biopsy prophylaxis is required, follow local transperineal or transrectal protocols and resistance data. Opioids, corticosteroids and palliative radiotherapy may be needed for metastatic symptoms but require coordinated plans. Exact medicines, combinations, doses and durations evolve rapidly; verify current Indian approval, formulary, molecular eligibility and oncology protocol. Provide patients with toxicity contacts and never stop corticosteroids or anticancer medicines abruptly without specialist advice.
When to Refer
Refer to urology when digital rectal examination is suspicious, PSA remains concerning after contextual repeat assessment, MRI is suspicious, haematuria is unexplained, or clinical features suggest locally advanced disease. Referral should communicate the PSA trend, medicines, infection or instrumentation history, examination, renal function, comorbidity, family history and the patient’s testing preferences. Do not make one fixed PSA threshold the sole gatekeeper, because age, gland volume, trend and examination change risk. Confirmed cancer belongs in a urological oncology multidisciplinary team with pathology and radiology review before definitive treatment. Involve radiation and medical oncology early for unfavourable localised, locally advanced, node-positive, metastatic or recurrent disease rather than waiting for sequential failure. Refer for genetic counselling and germline testing when age, aggressive phenotype, metastatic disease or family pattern meets current criteria; results can affect relatives and sometimes treatment. Continence physiotherapy, erectile-function and psychosexual support should begin before or soon after radical treatment where available. Bone health, cardiology, diabetes, geriatrics or anaesthetic review may be required to make treatment safer. Palliative care is appropriate alongside disease-directed therapy when pain, complex symptoms or difficult decisions arise. Emergency referral is mandatory for suspected cord compression, sepsis, clot retention, acute kidney injury from obstruction, uncontrolled haematuria or rapidly deteriorating performance. In Indian systems with variable access, an effective referral names an appropriate centre, conveys urgency, transfers imaging and pathology, gives safety-net instructions and confirms that the patient can actually reach the next service.
Red Flags
New severe back pain with night pain, radicular symptoms, leg weakness, sensory change, gait difficulty, saddle numbness or new bladder or bowel dysfunction may indicate metastatic spinal cord or cauda equina compression. Treat this as an oncological emergency: arrange urgent senior assessment and spinal imaging through the local pathway without waiting for a routine PSA appointment. Anuria, oliguria, rising creatinine, bilateral hydronephrosis, a painful distended bladder or sepsis with obstruction requires urgent decompression planning. Fever, rigors, hypotension or confusion after prostate biopsy can represent life-threatening infection, particularly after a transrectal procedure. Heavy haematuria with clots, retention, syncope or falling haemoglobin needs emergency urological assessment. In a person receiving systemic treatment, fever, new breathlessness, chest pain, focal neurological deficit, severe diarrhoea, jaundice, profound weakness or inability to hydrate may reflect neutropenia, thrombosis, cardiovascular toxicity, hepatic injury or another treatment complication. Worsening pain, pathological fracture or hypercalcaemic symptoms can signal advanced skeletal disease even when PSA behaviour is atypical. A low PSA must not falsely reassure when aggressive variant disease is clinically suspected. Red flags trigger action but do not determine the diagnosis. Stabilise airway, breathing and circulation; obtain cultures and blood tests when appropriate; control pain; and contact urology, oncology or spinal services immediately. Every patient starting treatment should receive written instructions explaining urgent symptoms and a reachable local number outside clinic hours.
Indian Clinical Context
The 2023 ICMR consensus is unusually valuable because it addresses Indian diagnostic availability, transperineal biopsy, conventional imaging, PSMA PET/CT, active surveillance, surgery, radiotherapy, systemic therapy and palliation within one national expert document. It is explicitly a non-binding consensus and acknowledges that clinicians may choose alternatives after discussion with patients and institutions. Apply that principle. Access to high-quality prostate MRI, experienced radiologists, transperineal biopsy, robotic surgery, modern radiotherapy, nuclear medicine, germline testing and newer systemic agents varies considerably across India. A test is useful only when its result can be interpreted and acted upon. If optimal imaging is unavailable, document the limitation and arrange referral or an evidence-based alternative rather than pretending equivalence. Out-of-pocket cost, travel, repeated injections and loss of work can change adherence; bilateral orchidectomy, conventional imaging or locally available radiotherapy may be rational choices for some patients when presented honestly. Do not assume a universal Indian PSA-screening age, interval or fast-track threshold. Decisions for asymptomatic testing require local policy and shared discussion of overdiagnosis as well as benefit. Registry data are geographically bounded and cannot supply one patient’s prognosis. Provide pathology slides or blocks, MRI images, stage, Grade Group, PSA chronology and treatment summary when care moves between centres. Consent should use the patient’s preferred language and cover continence, sexuality, fertility, bowel effects, hot flushes, metabolic health and costs. current guidelines guidance can inform reasoning, but it reflects UK pathways and has planned updates after 2025 surveillance; it is not Indian policy.
NMC Competency Mapping
NMC CBME Curriculum 2024 gives a precise core pathology anchor in PA28.4: learners should describe the pathogenesis, pathology, hormonal dependence, presentation, distinguishing features, diagnostic tests, progression and spread of carcinoma of the prostate. PA28.6 adds supervised description and identification of morphologic and microscopic features of male genital tract diseases and tumours. These competencies justify teaching the relationship between androgen signalling, acinar adenocarcinoma, Gleason patterns, ISUP Grade Groups, perineural invasion and common routes of spread. They also require comparison with benign prostatic hyperplasia and prostatitis rather than a cancer-only list. A clinically integrated session should teach why PSA is not cancer-specific, how digital rectal examination changes suspicion, what multiparametric MRI contributes, and why histology is required before most definitive treatment. Students should interpret a concise case using PSA, examination, MRI, biopsy grade and TNM rather than prescribe independently. Communication teaching should cover uncertainty after a raised PSA, biopsy harms, active surveillance, continence, sexual function and treatment preference. A pathology spotter, structured viva and written clinicopathological problem can assess the named outcomes; clinical examination must remain consented and supervised. Mapping does not mean that an undergraduate is competent to select androgen-receptor agents, plan radiotherapy or perform biopsy. This guide therefore labels specialist treatment detail as educational context and does not invent a urology management competency code absent from the cited curriculum table.
Key Exam Pearls for NEET PG
Most prostate cancers are acinar adenocarcinomas in the peripheral zone, whereas benign prostatic hyperplasia classically affects the transition or periurethral zone. PSA is prostate-specific, not cancer-specific; infection, retention, manipulation, benign enlargement and 5-alpha-reductase inhibitors alter interpretation. A hard irregular gland is concerning, but normal digital rectal examination does not exclude disease. Multiparametric MRI precedes biopsy in modern pathways where available and guides targeted sampling; histology supplies Gleason score and ISUP Grade Group. Distinguish 3 plus 4 from 4 plus 3 because the predominant pattern changes risk. Transperineal biopsy has a lower infectious risk than the transrectal route. Localised low-risk disease may undergo active surveillance, which is scheduled curative-intent monitoring, whereas watchful waiting is symptom-led management for people unlikely to benefit from cure. Radical prostatectomy and radiotherapy have different urinary, sexual and bowel adverse-effect profiles. Androgen deprivation is foundational in metastatic disease, but fit patients commonly need systemic intensification. A gonadotropin-releasing hormone agonist can cause tumour flare; an antagonist does not. Prostate cancer bone metastases are classically osteoblastic, yet fractures and cord compression still occur. In an examination stem, back pain with weakness or sphincter disturbance is metastatic spinal cord compression until urgently assessed. PSA recurrence definitions depend on the primary treatment and should not be mixed. PSMA PET/CT can detect disease at lower burden but does not replace histology or clinical judgement. For any management answer, state risk group, life expectancy, patient preference and multidisciplinary review before choosing treatment.
Frequently Asked Questions
Does an elevated PSA blood test confirm that a man has prostate cancer?
No. PSA can rise with benign enlargement, inflammation, retention and recent urinary procedures, and some clinically important cancers have only modest PSA elevation. Interpret the value with previous results, medicines, examination, prostate volume, MRI and overall health. When clinically safe, an unexpected result may be repeated under standardised conditions. Histopathology, not PSA alone, confirms cancer.
Why might a confirmed prostate cancer be monitored instead of treated immediately?
Some localised cancers have a low probability of causing harm during the patient’s lifetime, while surgery or radiotherapy can affect continence, erections and bowel function. Structured active surveillance preserves the option of cure while monitoring for evidence of greater risk. It is appropriate only after careful staging and risk classification, with reliable follow-up and agreed triggers for reassessment or treatment.
Is multiparametric MRI enough to exclude prostate cancer without a biopsy?
Not in every patient. A low-suspicion MRI reduces the likelihood of clinically significant cancer but does not make it zero. The biopsy decision also uses PSA density and trend, digital rectal examination, family history, prior biopsy, age, comorbidity and patient preference. When suspicion remains high, specialist review and systematic and/or targeted biopsy may still be appropriate.
Can a UK prostate cancer guideline be applied directly to Indian practice?
It can inform evidence-based reasoning but is not Indian policy. MRI, biopsy routes, imaging, radiotherapy, medicines, funding and follow-up systems differ, and international guidelines has identified areas for further updating after 2025 surveillance. The 2023 ICMR consensus supplies Indian context. Final care should follow current Indian approvals, local protocols, multidisciplinary review and the patient’s priorities and resources.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic